A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor

This is the authors' abstract. We don't add key points for this paper.

Recent advances in the treatment of multiple myeloma (MM) using newly developed drugs, such as thalidomide, lenalidomide and bortezomib, have improved the survival of the patients with refractory disease. However, it remains difficult to treat certain populations of MM patients; these patients are considered high-risk cases. Tumor cells obtained from these patients conferred characteristic chromosomal abnormalities, including deletion of chromosome 13 (del 13), t(4;14) translocation and deletion of chromosome 17, on which tumor suppressor gene TP53 is localized. 1 , 2 , 3 , 4 Here we report the establishment of a novel myeloma cell line, MUM24, which was obtained from the bone marrow of a 64-year-old female patient with immunoglobulin G (IgG) (k)-type MM. She was refractory to melphalan plus prednisolone, vincristine plus doxorubicin plus dexamethasone and high-dose dexamethasone as well as thalidomide. A bone marrow sample was obtained in September 2002, and was used for establishing the MUM24 cell line. The patient passed away in December 2002 due to systemic progression of the MM, including intracranial invasion.